Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
232
resultados
Última actualización
07/06/2025 [07:52:00]
Resultados 25 a 50 de 232
Resumen de: US2025177318A1
Provided are functional segregated telodendrimers having, for example, two or three functional segments. The telodendrimers can aggregate to form nanocarriers. The telodendrimers can have one or more tetracycline drugs (such as CMT-3) physically bound thereto that release under physiological conditions. Such nanocarriers with loaded CMT-3 disperse stably in aqueous solution and may be used in treating inflammatory disease through local or systemic administration. Also provided are methods of treating acute respiratory distress syndrome (ARDS) and/or CARDS in a subject in need thereof, including: administering a therapeutically effective amount of CMT-3 and one or more nonantimicrobial host-modulators directly to the lungs of the patient. In embodiments, CMT-3 is administered to the lungs in an aerosolized formulation. In embodiments, subsequent to CMT-3 administration, one or more non-antimicrobial host-modulators directly to the lungs of the patient.
Resumen de: US2025177319A1
A bacteria-responsive color-changing, core-shell nanofiber, comprising polyurethane (PU), a hemicyanine-based chromogenic probe localized in the core-shell nanofiber near the surface of the shell, polyvinylpyrrolidone (PVP) dopant in the shell, the hemicyanine-based chromogenic probe further comprising a labile ester linkage that is enzymatically cleavable by bacterial lipase released from clinically relevant strains of bacteria including Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus (MRSA).
Resumen de: US2025177317A1
A lipid nanoparticle based composition and method for making the same is provided. The lipid nanoparticle based composition includes an in-vitro transcribed (IVT) mRNA molecule containing (a) a 5′ cap structure, (b) a coding region encoding an antigen polypeptide, (c) an immunostimulatory RNA sequence that activates RIG-I, (d) a poly (A) tail, and (e) a TLR antagonist based on a phospholipid.
Resumen de: US2025177437A1
Some embodiments include methods of treating, inhibiting, or ameliorating ischemic stroke or a symptom thereof in a subject. Some embodiments include oxygenated fluid for use in treating, inhibiting, or ameliorating ischemic stroke. The oxygenated fluid may comprise charge-stabilized oxygen-containing nanostructures.
Resumen de: US2025177432A1
This disclosure provides compositions and methods for treating cancers. The compositions include mRNA molecules encoding proteins useful for treating the cancers, such as IL-12, an OX40 agonist, and optionally along with FADD, MLKL or MLKL-4HB. The mRNA can include 5′UTR and 3′UTR sequences and 5′cap structures that improve the stability and/or therapeutic effects of these mRNA molecules.
Resumen de: US2025177301A1
A multi-layer (multi-lamellar) coated nanoparticle is provided wherein the nanoparticle comprises a first coat comprising a positively charged polymer or a positively charged lipd bilayer and a second coat comprising an anionic bilayer and optionally one or more distinct cargo molecules, one or more distinct targeting moieties, or any combination thereof, as well as methods of making and using the nanoparticle.
Resumen de: AU2023391361A1
Provided are aerosolized pharmaceutical compositions including aerosol particles, the aerosol particles comprising lipid nanoparticles (LNPs). Also provided herein are liquid pharmaceutical compositions for use in making aerosolized pharmaceutical compositions. Also provided herein are methods of administering the aerosolized pharmaceutical compositions. Also provided herein are kits including a lipid nanoparticle composition including one or more of a phospholipid, an ionizable lipid, a PEG-lipid, a sterol.
Resumen de: AU2023385865A1
Disclosed herein are dense nanolipid fluid (DNLF) dispersions comprising desirable characteristics for incorporating bioactive agents such as peptides into lipid phase of the dispersion for biodelivery of the agents for their typical purpose. Continuous methods for preparing the DNLF dispersions are also disclosed herein to include formation of a crude mill base and passing the base through a twin screw extruder. Dispersions disclosed herein can express a particle size of less than 150 nm under stable storage conditions, while forming lamellar structures after exposure to heat and/or evaporation of the aqueous components of the dispersion.
Resumen de: AU2023378958A1
The present invention provides delivery system compositions comprising self- assembling lipid nanoparticles for targeted delivery of therapeutic or diagnostic agents to target cells. The particles are non-covalently attached to a lipidated antibody or antibody fragment which comprises an antibody or antibody fragment attached, via a peptide linker, to a lipidated peptide portion, wherein the antibody or antibody fragment is at the distal end from the nanoparticle.
Resumen de: WO2025117906A1
Described herein are microfluidic approaches for the assembly of nanoparticles manufactured from isolated red blood cell (RBC) lipids and components. The engineered nanoparticles (e.g., vesicles) can be used to encapsulate cargo, including active agents such as proteins, nucleic acids (e.g., RNA), and other classes of therapeutic agents. Optionally, the vesicles can be further functionalized with targeting agents.
Resumen de: WO2025117832A1
Nanoparticles comprising miR-211 and their use for treating brain cancers, such as medulloblastomas, including pediatric medulloblastomas, are disclosed.
Resumen de: WO2025117815A1
Provided are lipid nanoparticles compositions comprising a payload, a helper lipid, a sterol, a PEG-lipid, an ionizable lipid, a permanently cationic lipids. Also provided herein are a method of delivering a payload to a cell in a lung of a subject by intravenous administration and a method for treating and/or preventing a lung disease in a subject in need thereof by intravenous administration. Also provided are a method for quantifying an amount of capped messenger RNA (mRNA) in an mRNA sample comprising contacting the mRNA with two or more of a nuclease, an alkaline phosphatase, and a polynucleotide kinase and separating the capped mRNA and the uncapped mRNA occurs using chromatography.
Resumen de: WO2025116441A1
The present disclosure relates to a pharmaceutical composition for preventing or treating osteoarthritis. The pharmaceutical composition for preventing or treating osteoarthritis according to the present disclosure is not only highly stable, thereby exhibiting excellent therapeutic effects, but is also expected to be a disease-modifying osteoarthritis drug (DMOAD)-class therapeutic agent that can prevent and preemptively treat osteoarthritis by overcoming the limitations of cell therapeutic agents through the use of mRNA.
Resumen de: WO2025117817A1
Provided are aerosolized pharmaceutical compositions including comprising aerosol particles, the aerosol particles comprising lipid nanoparticles (LNPs), the LNP comprising at least two selective organ targeting (SORT) lipids and/or at least six lipids. Also provided herein are methods of administering the aerosolized pharmaceutical compositions described herein.
Resumen de: WO2025117822A1
Described herein are self-assembled peptides and hydrogels comprising self-assembled peptides and glucose. Exemplary hydrogels comprising self-assembled peptides and glucose may be used to encapsulate glucagon and/or a glucagon analogue. Hydrogels with glucagon and/or a glucagon analogue encapsulated therein may be used to treat hypoglycemia and related disorders in subjects in need thereof.
Resumen de: WO2025117816A1
Disclosed herein are lipid nanoparticles (LNPS) and pharmaceutical compositions and vaccines comprising same. Also disclosed herein are methods of administering an LNP composition, pharmaceutical compositions, and vaccines described herein for preventing an infectious disease and/or for immunizing a subject or for delivering a payload to a cell in the central nervous system (CNS) of a subject. Also provided are methods for treating and/or preventing a CNS disease.
Resumen de: WO2025117732A1
The present disclosure provides for improved compositions of ionizable lipid nanoparticles for the delivery of therapeutic nucleic acids to cells. Anionic phospholipids, including phosphatidylserine and phosphatidylglycerol are included in the lipid nanoparticles to increase the transfection efficiency in human dendritic cells. The further incorporation of mono-unsaturated alkyl chain analogs in dimethylaminopropyl-dioxolane or heterocyclic ketal ionizable lipids in the formulation demonstrated high levels of transfection in human dendritic cells, compared to other ionizable lipids in the same family, and demonstrated good stability to oxidative damage. Finally, the use of an ammonium salt of phosphatidylserine allows for the efficient production of PS-targeted LNPs.
Resumen de: WO2025116177A1
The present invention relates to a pharmaceutical composition comprising mesenchymal stem cells overexpressing interleukin-10 (IL-10), poly-L-lactic acid particles, and hydrogel, wherein the composition has remarkably excellent adhesion and proliferation abilities of stem cells with a medicinal effect on degenerative arthritis, thereby exhibiting an excellent medicinal effect on degenerative arthritis.
Resumen de: WO2025116961A1
The disclosed technology includes cannabinoid oral products, and methods for making same. In some embodiments, the oral products are pouches including cannabinoid infused wafers. In some embodiments, the method of making the cannabinoid oral products includes preparing an emulsion, preparing a spray dry solution, spray drying solution into cannabinoid and carbohydrate particles, preparing a paste, preparing a wafer in a heated vacuum oven, fragmenting the wafer into cannabinoid infused wafer fragments, mixing the cannabinoid infused wafer fragments with starch, and dispensing the cannabinoid infused wafer fragments into pouches. The methods may also include labeling the oral products, for example, with a THC warning symbol.
Resumen de: WO2025116530A1
The present invention relates to nanoparticles comprising sirolimus and albumin, a pharmaceutical composition for subcutaneous administration, comprising same, and a preparation method therefor. If the preparation method of the present invention is used, nanoparticles comprising sirolimus and albumin and having excellent improved particle size distribution maintenance stability can be prepared, and the prepared nanoparticles can be prepared in a pharmaceutical composition suitable for subcutaneous injection, and thus dosage is increased and convenience of administration is improved.
Resumen de: WO2025116522A1
The present invention relates to silica-based nanoparticles for sustained release of a hydrophilic drug and a manufacturing method thereof, the nanoparticles comprising: silica-based hollow nanoparticles comprising a hollow core layer and a silica matrix shell layer infiltrated with metal; and a hydrophilic drug supported by the hollow nanoparticles.
Resumen de: WO2025113478A1
A tumor nano-vaccine and a preparation method therefor, belonging to the technical field of biopharmaceuticals. The tumor nano-vaccine comprises tumor cell lysate nanoparticles. The tumor cell lysate nanoparticles are formed by taking an acryloyl ester as a monomer, utilizing a biodegradable cross-linking agent, and synthesizing in situ a nano-thickness polymer shell on the surface of a protein or a tumor specific antigen in a tumor cell lysate by utilizing a free radical polymerization reaction. The tumor cell lysate nanoparticles can enhance the immunogenicity of a tumor antigen, thereby improving the immune response of an organism to a tumor. The tumor nano-vaccine enhances the stability of the tumor antigen, thereby ensuring the in vivo persistent circulation of the tumor antigen, and induces the organism to generate cell immunity and activate T cells, thereby achieving the effect of treating and/or preventing tumors.
Resumen de: WO2025113656A1
An ionizable cationic lipid compound having a structure represented by formula (I), which can be used to prepare lipid nanoparticles (LNP) for the delivery of a therapeutic and/or prophylactic agent. The LNP prepared using the ionizable cationic lipid compound has good stability and transfection efficiency, and can efficiently and stably deliver bioactive substances (including nucleic acids, such as mRNA) to target cells or organs, thereby eliciting a high-specificity antibody response in vivo.
Resumen de: WO2025113654A1
An ionizable cationic lipid compound having a structure as represented by formula (I), which can be used for preparing a lipid nanoparticle (LNP) for the delivery of a therapeutic agent and/or a prophylactic agent. The LNP prepared with the ionizable cationic lipid compound has a better stability and transfection efficiency, and can efficiently and stably deliver a bioactive substance (comprising a nucleic acid, e.g., mRNA) to a target cell or organ, thereby eliciting a highly specific antibody response in vivo.
Nº publicación: WO2025116518A1 05/06/2025
Solicitante:
INBCT CO LTD [KR]
\uC778\uBE44\uC528\uD2F0 \uC8FC\uC2DD\uD68C\uC0AC
Resumen de: WO2025116518A1
The present invention relates to a pharmaceutical composition and an oral composition, which comprise nano-graphene oxide or a variant thereof for preventing or treating oral diseases, wherein the nano-graphene oxide or the variant thereof can prevent and treat various oral diseases including gingivitis through antibacterial, anti-inflammatory and osteoclast differentiation-promoting factor reduction effects in the oral cavity, and thus the present invention can be applied to various oral care products.
BOPI
Sede Electrónica
